Download Files:
BMS-986094
$190 – $1,500
Products Details
Product Description
– BMS-986094 (INX-08189) is a potent inhibitor of hepatitis C virus (HCV) replication, with an EC50 of 35 nM at 24 h in Huh-7 cells. BMS-986094 is a phosphoramidate proagent of 6-O-methyl-2’-C-methyl guanosine. BMS-986094 can be used for the research of chronic HCV infection[1][2].
Web ID
– HY-13337
Storage Temperature
– -20°C, 3 years; 4°C, 2 years (Powder)
Shipping
– Room Temperature
Applications
– COVID-19-anti-virus
Molecular Formula
– C30H39N6O9P
References
– [1]Vernachio JH, et, al. INX-08189, a phosphoramidate prodrug of 6-O-methyl-2′-C-methyl guanosine, is a potent inhibitor of hepatitis C virus replication with excellent pharmacokinetic and pharmacodynamic properties. Antimicrob Agents Chemother. 2011 May; 55(5): 1843-51.|[2]McGuigan C, et, al. Design, synthesis and evaluation of a novel double pro-drug: INX-08189. A new clinical candidate for hepatitis C virus. Bioorg Med Chem Lett. 2010 Aug 15; 20(16): 4850-4.|[3]Li W, et, al. In Vitro Metabolite Formation in Human Hepatocytes and Cardiomyocytes and Metabolism and Tissue Distribution in Monkeys of the 2′-C-Methylguanosine Prodrug BMS-986094. Int J Toxicol. 2017 Jan 1; 1091581816683642.
CAS Number
– 1234490-83-5
Molecular Weight
– 658.64
Compound Purity
– 99.90
SMILES
– C[C@]([C@](O[C@@H]1CO[P](OC2=CC=CC3=C2C=CC=C3)(N[C@@H](C)C(OCC(C)(C)C)=O)=O)([H])N4C5=NC(N)=NC(OC)=C5N=C4)([C@@H]1O)O
Clinical Information
– Phase 2
Research Area
– Infection
Solubility
– DMSO : 250 mg/mL (ultrasonic)
Target
– HCV
Pathway
– Anti-infection
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
